Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Background: Parkinson's disease (PD) is the second most common neurodegenerative disease, after Alzheimer’s disease, affecting approximately one million persons aged 65 years and above in the United States. Parkinson's disease represents a major medical concern for health professionals, national healthcare bodies and a heavy burden for caregivers. Heart failure occurred twice as frequently in elderly PD patients as in non-PD patients. There is paucity of information on the association of patient and hospital characteristics on the outcomes of inpatient with both congestive heart failure and Parkinson disease. Congestive Heart Failure with PD as a comorbidity will increase the cost of care and health resources. We investigate on the current prevalence and factors that affect the inpatient with both CHF and PD conditions using a longitudinal datasets from National Inpatient Samples. The results obtained from this study will provide information that will reduce frequent readmission, length of stay, total charges and mortality rate in this population. Methods: Data from the National Inpatient Samples (NIS) were extracted and analyzed using ICD 9 codes (CHF 428, PD 332) for the main diagnosis. For continuous variables, we calculated the mean and standard deviations and evaluated significant differences of these factors by Parkinson disease status using the t-test. For categorical variables, we obtained the counts (proportions) and evaluated significant differences using the Chi-square and Fisher’s exact test Propensity score was utilized to match age, gender and race using logistic model for hospital death and generalized linear model for length of stay (LOS) and hospital charges. Result: The overall frequency of Parkinson disease (PD) in congestive heart failure was 1.54 % (n = 10,748). PD patients with CHF were more likely to be males (53.13 %; 5462) and Caucasians (82.24 %; n=8454). The average age of inpatient was approximately 80 years (SD=8.05). Hospital admission, decreases with median household income. Patients with low income ($1 - $38,999) were admitted more with 3002 (29.70%) than those with higher income ($63,000 and more) with 2230 (22.06%). Length of stay (LOS) (p 1.000). Similarly, hospital death rates (%) were not different (P>1.000), although hospital length of stay (P<1.000) and total charge incurred during hospitalization were less in patients with PD (p < 0.005)

[1]  A. Kaplin,et al.  HOW COMMON ARE THE “COMMON” NEUROLOGIC DISORDERS? , 2007, Neurology.

[2]  M. Kamal,et al.  An overview on the correlation of neurological disorders with cardiovascular disease , 2014, Saudi journal of biological sciences.

[3]  R. Hauser,et al.  Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. , 2004, Parkinsonism & related disorders.

[4]  K. Nagata,et al.  High Prevalence of Gastroesophageal Reflux Disease in Parkinson's Disease: A Questionnaire-Based Study , 2013, Parkinson's disease.

[5]  D. Maraganore,et al.  Comorbid conditions associated with Parkinson's disease: A population‐based study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[6]  C. C. Johnson,et al.  Parkinson's disease and its comorbid disorders , 1994, Neurology.

[7]  R. Hamill,et al.  Parkinson's disease. , 2012, Sub-cellular biochemistry.

[8]  D. Weintraub,et al.  Depression in veterans with Parkinson's disease: frequency, co‐morbidity, and healthcare utilization , 2007, International journal of geriatric psychiatry.

[9]  Chung-Yi Li,et al.  Risk of Parkinson Disease Onset in Patients With Diabetes , 2012, Diabetes Care.

[10]  Tie-mei Zhang,et al.  Nonmotor symptoms in patients with Parkinson disease , 2016, Medicine.

[11]  M. Tagliati,et al.  Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. , 2015, Parkinsonism & related disorders.

[12]  M. Ziman,et al.  A Systematic Review and Meta-Analysis of Strength Training in Individuals With Multiple Sclerosis Or Parkinson Disease , 2015, Medicine.

[13]  G Hu,et al.  Body mass index and the risk of Parkinson disease , 2006, Neurology.

[14]  Bradley A. Evanoff,et al.  Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries , 2010, Neuroepidemiology.

[15]  E. Wolters,et al.  Management of non-motor symptoms in advanced Parkinson disease , 2008, Journal of the Neurological Sciences.

[16]  Xuemei Huang,et al.  Diabetes and Risk of Parkinson’s Disease , 2011, Diabetes Care.

[17]  M. Nance Therapy in Huntington’s Disease: Where Are We? , 2012, Current Neurology and Neuroscience Reports.

[18]  R. Barker,et al.  Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  Gerhard Ransmayr,et al.  Cognitive impairment in Parkinson's disease. , 2015, Psychiatria Danubina.

[20]  H. Fukuyama,et al.  Case–control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan , 2010, Journal of the Neurological Sciences.

[21]  H. Reichmann,et al.  Parkinson’s disease between internal medicine and neurology , 2015, Journal of Neural Transmission.

[22]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[23]  D. Huse,et al.  Burden of illness in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[24]  V. Roger Epidemiology of Heart Failure , 2013, Circulation research.